Medifoxamine: Difference between revisions
CSV import |
CSV import |
||
| Line 25: | Line 25: | ||
[[Category:Discontinued drugs]] | [[Category:Discontinued drugs]] | ||
[[Category:French drugs]] | [[Category:French drugs]] | ||
<gallery> | |||
File:Medifoxamine.svg|Medifoxamine | |||
</gallery> | |||
Revision as of 01:13, 20 February 2025
Medifoxamine is an antidepressant and anxiolytic drug that was formerly used in France for the treatment of depression and anxiety disorders, but has since been discontinued. Medifoxamine is a dopamine reuptake inhibitor, and is unique among most antidepressants in that it does not inhibit the reuptake of serotonin or norepinephrine. It also has anticholinergic properties.
Pharmacology
Medifoxamine acts as a dopamine reuptake inhibitor and sigma receptor agonist. It does not inhibit the reuptake of serotonin or norepinephrine. Medifoxamine also has anticholinergic properties, which can lead to side effects such as dry mouth, constipation, and cognitive impairment in some patients.
Medical uses
Medifoxamine was primarily used for the treatment of depression and anxiety disorders. It was particularly effective in patients with depression who also suffered from anxiety, due to its dual action as an antidepressant and anxiolytic.
Side effects
The most common side effects of medifoxamine include dry mouth, constipation, and cognitive impairment, which are likely due to its anticholinergic properties. Other side effects can include dizziness, nausea, and insomnia.
History
Medifoxamine was developed in the 1970s by the French pharmaceutical company Servier. It was marketed in France under the brand name Clédial. However, it has since been discontinued and is no longer available.


